Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 35 EV-to-EBITDA is 6.91 as of Sep. 21, 2026. GuruFocus rates BIOE with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 745 Drug Manufacturers companies, Bio Essence ranks better than 76.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bio Essence's enterprise value is $11.36 Mil.
Bio Essence's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $1.64 Mil. Therefore, Bio Essence's EV-to-EBITDA for today is 6.91.
The historical rank and industry rank for Bio Essence's EV-to-EBITDA or its related term are showing as below:
BIOE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1970.94 Med: -33.41 Max: 18.17
Current: 6.91
During the past 9 years, the highest EV-to-EBITDA of Bio Essence was 18.17. The lowest was -1970.94. And the median was -33.41.
BIOE's EV-to-EBITDA is ranked better than 76.38% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs BIOE: 6.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio Essence's PE Ratio (TTM) for today is calculated as:
Bio Essence's share price for today is $0.1819.
Bio Essence's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.037.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bio Essence's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bio Essence's EV-to-EBITDA falls into.
Bio Essence's current Enterprise Value is $11.36 Mil.
Bio Essence's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence (BIOE) has a EV-to-EBITDA of 6.91 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bio Essence. According to the industry distribution chart, Bio Essence ranks #176 out of 745 companies in the Drug Manufacturers industry, placing it in the top 23.6%.
Is Bio Essence's EV-to-EBITDA too high?
Bio Essence's current EV-to-EBITDA is 6.91. The Drug Manufacturers industry median EV-to-EBITDA is 12.56. Bio Essence's value of 6.91 is 45% below this industry median. Based on the distribution chart, Bio Essence ranks #176 out of 745 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Essence has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's EV-to-EBITDA compare to INM and SNOA?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #176 out of 745 companies for EV-to-EBITDA. This places Bio Essence in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.56. Bio Essence's value of 6.91 is 45% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Essence's current EV-to-EBITDA of 6.91 is 45% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bio Essence. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Essence's current EV-to-EBITDA is 6.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current EV-to-EBITDA of 6.91. The current EV-to-EBITDA is 6.91 and 45% below the Drug Manufacturers industry median of 12.56. Bio Essence's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bio Essence (BIOE), the current EV-to-EBITDA is 6.91 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
35GF Score
Get the complete analysis for BIOE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
